Cargando…
A phase I study of the fully human, fragment crystallizable- engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883544/ https://www.ncbi.nlm.nih.gov/pubmed/34854276 http://dx.doi.org/10.3324/haematol.2020.274118 |
| _version_ | 1784659957694595072 |
|---|---|
| author | Vasu, Sumithira Altman, Jessica K. Uy, Geoffrey L. Tallman, Martin S. Gojo, Ivana Lozanski, Gerard Burkard, Ute Osswald, Annika James, Pamela Rüter, Björn Blum, William |
| author_facet | Vasu, Sumithira Altman, Jessica K. Uy, Geoffrey L. Tallman, Martin S. Gojo, Ivana Lozanski, Gerard Burkard, Ute Osswald, Annika James, Pamela Rüter, Björn Blum, William |
| author_sort | Vasu, Sumithira |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8883544 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88835442022-03-18 A phase I study of the fully human, fragment crystallizable- engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia Vasu, Sumithira Altman, Jessica K. Uy, Geoffrey L. Tallman, Martin S. Gojo, Ivana Lozanski, Gerard Burkard, Ute Osswald, Annika James, Pamela Rüter, Björn Blum, William Haematologica Letters to the Editor Fondazione Ferrata Storti 2021-12-02 /pmc/articles/PMC8883544/ /pubmed/34854276 http://dx.doi.org/10.3324/haematol.2020.274118 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letters to the Editor Vasu, Sumithira Altman, Jessica K. Uy, Geoffrey L. Tallman, Martin S. Gojo, Ivana Lozanski, Gerard Burkard, Ute Osswald, Annika James, Pamela Rüter, Björn Blum, William A phase I study of the fully human, fragment crystallizable- engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia |
| title | A phase I study of the fully human, fragment crystallizable- engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia |
| title_full | A phase I study of the fully human, fragment crystallizable- engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia |
| title_fullStr | A phase I study of the fully human, fragment crystallizable- engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia |
| title_full_unstemmed | A phase I study of the fully human, fragment crystallizable- engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia |
| title_short | A phase I study of the fully human, fragment crystallizable- engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia |
| title_sort | phase i study of the fully human, fragment crystallizable- engineered, anti-cd-33 monoclonal antibody bi 836858 in patients with previously-treated acute myeloid leukemia |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883544/ https://www.ncbi.nlm.nih.gov/pubmed/34854276 http://dx.doi.org/10.3324/haematol.2020.274118 |
| work_keys_str_mv | AT vasusumithira aphaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT altmanjessicak aphaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT uygeoffreyl aphaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT tallmanmartins aphaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT gojoivana aphaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT lozanskigerard aphaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT burkardute aphaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT osswaldannika aphaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT jamespamela aphaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT ruterbjorn aphaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT blumwilliam aphaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT vasusumithira phaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT altmanjessicak phaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT uygeoffreyl phaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT tallmanmartins phaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT gojoivana phaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT lozanskigerard phaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT burkardute phaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT osswaldannika phaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT jamespamela phaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT ruterbjorn phaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia AT blumwilliam phaseistudyofthefullyhumanfragmentcrystallizableengineeredanticd33monoclonalantibodybi836858inpatientswithpreviouslytreatedacutemyeloidleukemia |